Literature DB >> 7095921

The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans.

M L Aitio, H Allonen, J Kanto, R Mäntylä.   

Abstract

The pharmacokinetics of disopyramide and its metabolite mono-N-dealkyl-disopyramide (MND) were studied after a single oral and intramuscular dose and at steady state in healthy volunteers, after an intravenous dose in post-surgery patients, and after a single oral dose in two patients with renal insufficiency. After an oral dose in healthy volunteers the plasma elimination half-life of total disopyramide was 8.65 +/- 1.37 h, and that of the non protein-bound disopyramide, 4.74 +/- 1.20 h. The protein binding of disopyramide varied from 0.58 to nearly 1.0, and was concentration dependent. All subjects had detectable amounts of MND in plasma. Its elimination half-life was 12.9 +/- 6.43 h. The ratio of MND to disopyramide was 0.23 +/- 0.09 in plasma and 0.46 +/- 0.11 in urine. There was a close correlation (r = 0.868) between the renal clearances of free disopyramide and creatinine. The renal clearances of disopyramide (both free and total), MND, and creatinine varied with time; this resembled variation in the urine flow. The kinetics of one dose at steady state did not differ markedly from that of a single dose. The elimination half-lives of total disopyramide varied from 4.4 to 17.1 in post-surgery patients, and those of the renal patients were 10.6 and 8.7 h.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7095921

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  3 in total

1.  Suitability of various noninfinity area under the plasma concentration-time curve (AUC) estimates for use in bioequivalence determinations: relationship to AUC from zero to time infinity (AUC0-INF).

Authors:  M N Martinez; A J Jackson
Journal:  Pharm Res       Date:  1991-04       Impact factor: 4.200

2.  Anticholinergic activity in the serum of patients receiving maintenance disopyramide therapy.

Authors:  E Iisalo; L Aaltonen
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

3.  A comparison of the anticholinergic effects of two formulations of disopyramide in healthy volunteers.

Authors:  J Longmore; J L Berry; E Szabadi; C M Bradshaw
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.